FGFR Inhibitors
Santa Cruz Biotechnology now offers a broad range of FGFR Inhibitors. Acidic and basic fibroblast growth factors (FGFs) are members of a family of multifunctional polypeptide growth factors that stimulate proliferation of cells of mesenchymal, epithelial and neuroectodermal origin. Like other growth factors, FGFs act by binding and activating specific cell surface receptors. FGFR Inhibitors offered by Santa Cruz inhibit FGFR and, in some cases, other cell proliferation and growth factor related proteins. View detailed FGFR Inhibitor specifications, including FGFR Inhibitor CAS number, molecular weight, molecular formula and chemical structure, by clicking on the product name.
Items 11 to 14 of 14 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
FIIN-1 | 1256152-35-8 | sc-507236 | 5 mg | $800.00 | ||
"FIIN-1" (CAS 1256152-35-8) acts as an FGFR inhibitor by precisely targeting the receptor's tyrosine kinase domain. This interaction disrupts autophosphorylation, impeding downstream signaling pathways that contribute to cellular functions like growth and differentiation. | ||||||
AP 24534 HCl | 943319-70-8 free base | sc-396905 sc-396905A | 10 mg 50 mg | $112.00 $138.00 | ||
"AP 24534 HCl" is an FGFR inhibitor that operates by blocking the ATP-binding site within the FGFR tyrosine kinase domain. This obstruction prevents autophosphorylation and subsequent intracellular signaling pathways that play a role in cellular growth and differentiation. | ||||||
Pazopanib Hydrochloride | 635702-64-6 | sc-364564 sc-364564A | 10 mg 25 mg | $107.00 $230.00 | 1 | |
"Pazopanib Hydrochloride" (CAS 635702-64-6) functions as an FGFR inhibitor by targeting receptor tyrosine kinases. Its interaction with the ATP-binding pocket disrupts autophosphorylation, affecting downstream signaling pathways involved in cellular processes such as growth and differentiation. | ||||||
AZD4547 | 1035270-39-3 | sc-364421 sc-364421A | 5 mg 10 mg | $198.00 $309.00 | 6 | |
AZD4547 is an FGFR1-3 inhibitor that has been evaluated for various solid tumors with FGFR alterations. | ||||||